Accordingly, cannabinoid type 1 (CB1) receptor inhibition by synthetic drugs such as rimonabant (CB1 inverse agonist) have been shown to produce promising anti-obesity effects in both animal models and obese patients [9]. Here, CNR1 is linked to obesity disorder.